Crinetics Pharmaceuticals reports $10.3 million in Q1 2026 net product revenue and 232 new patient enrollments.
Crinetics Pharmaceuticals raised its Palsonify coverage target to exceed 75% by the end of Q3 2026, citing strong operational momentum. The company reported $10.3 million in net product revenue for Q1 2026, driven by 232 additional patient enrollments during the quarter.
Management highlighted progress across multiple fronts, reinforcing confidence in long-term growth. The company also secured funding to extend operations into 2030, reducing near-term liquidity concerns.
Shares of CRNX showed limited immediate reaction following the earnings call disclosure.